Visudyne (verteporfin)
- Region
- 🇪🇺 EU
- Active substance
- verteporfin
- Company
- CHEPLAPHARM Arzneimittel GmbH
- Status
- Authorised
- Therapeutic area
- Myopia, Degenerative; Macular Degeneration
- EU approval
- Thu 27 Jul 2000
- Application
- EMEA/H/C/000305
- ATC
- S01LA01
- Official record
- www.ema.europa.eu
Indication
Visudyne is indicated for the treatment of: adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or; adults with subfoveal choroidal neovascularisation secondary to pathological myopia.
Regulatory milestones
Fri 04 Sep 2026🇪🇺 EU shortage
Visudyne: shortage ongoing
Powder for solution for infusion; Expected resolution: 2027; Alternatives available: Yes · source
Follow Visudyne
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.